子宫内膜异位症恶变

doi:10.6040/j.issn.1671-7554.0.2019.494

摘要/Abstract

摘要： 子宫内膜异位症是子宫内膜间质及腺体在子宫腔以外部位浸润生长导致的一类疾病,见于育龄期女性。在临床实践中发现,子宫内膜异位症虽然是个良性疾病,但其仍有恶变的风险。本文从子宫内膜异位症与卵巢癌发病关系、其恶变高危因素、恶变的相关分子机制及如何预防子宫内膜异位症恶变的发生进行阐述与探讨。

关键词: 子宫内膜异位症恶变, 子宫内膜异位症, 卵巢癌, 抑癌基因, 氧化应激反应

Abstract: Endometriosis, characterized by the presence of extra-uterine endometrium, is a common gynecologic disorder in reproductive-age women. In clinical practice, although endometriosis is recognized as a benign disease, it still has the risk of malignant change. This review mainly presents the relationship between endometriosis and ovarian tumors, and probes into the risk factors, molecular mechanism and prevention of malignant transformation.

Key words: Malignant transformation, Endometriosis, Ovarian tumor, Tumor suppressor genes, Oxidative stress

中图分类号:

R737.3

刘崇东,娄彤,董靖. 子宫内膜异位症恶变[J]. 山东大学学报 (医学版), 2019, 57(6): 27-32.

LIU Chongdong, LOU Tong, DONG Jing. Malignant transformation of endometriosis[J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 27-32.

参考文献

[1] ViganòP, Parazzini F, Somigliana E, et al. Endometriosis: epidemiology and aetiological factors [J]. Best Pract Res Clin Obstet Gynaecol, 2004, 18(2):177-200.
[2] Hickey M, Ballard K, Farquhar C. Endometriosis [J]. BMJ(Clinical research ed.), 2014, 348: g1752. doi: 10.1136/bmj.g1752.
[3] Halme J, Hammond MG, Hulka JF, et al. Retrograde menstruation in healthy women and in patients with endometriosis [J]. Obstet Gynecol, 1984, 64(2): 151-154.
[4] Abrao MS, Podgaec S, Dias JA Jr., et al. Deeply infiltrating endometriosis affecting the rectum and lymph nodes [J]. Fertil Steri, 2006, 86(3): 543-547.
[5] Guo SW, Zilberberg MD, Hummelshoj L. Endometriosis and Ovarian cancer [J]. Lancet Oncol, 2012, 13(5): e189-190. doi: 10.1016/S1470-2045(12)70199-7.
[6] Jiang X, Morland SJ, Hitchcock A, et al. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage[J]. Cancer Res, 1998, 58(8): 1707-1712.
[7] Somigliana E, Vigano P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence[J]. Gynecol Oncol, 2006, 101(2): 331-341.
[8] Wang S, Qiu L, Lang JH, et al. Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis[J]. Am J Obstet Gynecol, 2013, 208(5): 413. doi: 10.1016/j.ajog.2012.12.004.
[9] Lee WL, Chang WH, Wang KC, et al. The risk of epithelial ovarian cancer of women with endometriosis may be varied greatly if diagnostic criteria are different: a nationwide population-based cohort study [J].Medicine(Baltimore), 2015, 94(39):e1633.
[10] Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies [J]. Lancet Oncol, 2012, 13(4):385-394.
[11] Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility[J]. Fertil Steril, 2004, 82(2): 405-414.
[12] Wang KC, Chang WH, Lee WL, et al. An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis[J]. BMC Cancer, 2014, 14: 831. doi: 10.1186/1471-2407-14-831.
[13] Kobayashi H, Sumimoto K, Kitanaka T, et al. Ovarian endometrioma—risks factors of ovarian cancer development [J]. Eur J Obstet Gynecol Reprod Biol, 2008, 138(2): 187-193.
[14] Thomsen LH, Schnack TH, Buchardi K, et al. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review[J]. Acta Obstet Gynecol Scand, 2017, 96(6):761-778.
[15] Kadan Y, Fiascone S, McCourt C, et al. Predictive factors for the presence of malignant transformation of pelvic endometriosis[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 185:23-27. doi: 10.1016/j.ejogrb.2014.11.029.
[16] Sekizawa A, Amemiya S, Otsuka J, et al. Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes [J]. Med Electron Microsc, 2004, 37(2):97-100.
[17] Otsuka J, Okuda T, Sekizawa A, et al. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma [J]. Med Electron Microsc, 2004, 37(3):188-192.
[18] Martini M, Ciccarone M, Garganese G, et al. Possible involvement of hMLH1, p16(INK4a)and PTEN in the malignant transformation of endometriosis [J]. Int J Cancer, 2002, 102(4):398-406.
[19] Obata K, Hoshiai H. Common genetic changes between endometriosis and ovarian cancer [J]. Gynecol Obstet Invest, 2000, 50(Suppl 1):39-43.
[20] Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary[J]. Cancer Res, 2000, 60(24): 7052-7056.
[21] Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas [J]. N Engl J Med, 2010, 363(16):1532-1543.
[22] Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma[J]. Science, 2010, 330(6001):228-231.
[23] Ishikawa M, Nakayama K, Nakamura K, et al. Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients[J]. Oncotarget, 2018, 9(19): 14754-14763.
[24] Akahane T, Sekizawa A, Purwosunu Y,et al. The role of p53 mutation in the carcinomas arising from endometriosis [J]. Int J Gynecol Pathol, 2007, 26(3):345-351.
[25] Bayramoglu H, Duzcan E. Atypical epithelial changes and mutant p53 gene expression in ovarian endometriosis [J]. Pathol Oncol Res, 2001, 7(1):33-38.
[26] Senthong A, Kitkumthorn N, Rattanatanyong P, et al. Differences in LINE-1 methylation between endometriotic ovarian cyst and endometriosis-associated ovarian cancer [J]. Int J Gynecol Cancer, 2014, 24(1):36-42.
[27] Guo C, Ren F, Wang D, et al. RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis [J]. Oncology Rep, 2014, 32(6): 2580-2588.
[28] Perez-Janices N, Blanco-Luquin I, Torrea N, et al. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis [J]. Oncotarget, 2015, 6(27): 23944-23958.
[29] Suryawanshi S, Vlad AM, Lin HM, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer [J]. Clin Cancer Res, 2013, 19(5): 1213-1224.
[30] Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries [J]. PLoS One, 2009,4(4):e5311. doi: 10.1371/journal.pone.0005311.
[31] Teague EM, Print CG, Hull ML. The role of microRNAs in endometriosis and associated reproductive conditions [J]. Hum Reprod Update, 2010, 16(2):142-165.
[32] Tian X, Xu L, Wang P. MiR-191 inhibits TNF-alpha induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1 [J]. Int J Clin Exp Pathol, 2015,8(5):4933-4942.
[33] Panda H, Pelakh L, Chuang TD, et al. Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKKbeta, KLF9, and FBLN5 [J]. Reprod Sci, 2012, 19(8):786-796.
[34] Iwabuchi T, Yoshimoto C, Shigetomi H, et al. Oxidative stress and antioxidant defense in endometriosis and its malignant transformation[J]. Oxid Med Cell Longev, 2015, 2015:848595. doi: 10.1155/2015/848595.
[35] Jeney V, Eaton JW, Balla G, et al. Natural history of the bruise: formation, elimination, and biological effects of oxidized hemoglobin[J]. Oxid Med Cell Longev, 2013, 2013:703571. doi: 10.1155/2013/703571.
[36] Chobot V, Hadacek F. Iron and its complexation by phenolic cellular metabolites: from oxidative stress to chemical weapons [J]. Plant Signal Behav, 2010, 5(1):4-8.
[37] Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects [J]. Antioxid Redox Signal, 2013,18(17):2352-2363.
[38] Hevir N, Ribic-Pucelj M, Lanisnik Rizner T. Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: a source of excessive hydroxy-estrogens and ROS? [J]. Mol Cell Endocrinol, 2013, 367(1-2):74-84
[39] Kobayashi H. Potential scenarios leading to ovarian cancer arising from endometriosis [J]. Redox Rep, 2016,21(3):119-126.
[40] Melin AS, Lundholm C, Malki N, et al. Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian cancer [J]. Acta Obstet Gynecol Scand, 2013, 92(5):546-554.
[41] Pearce CL, Stram DO, Ness RB, et al. Population distribution of lifetime risk of ovarian cancer in the United States [J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(4):671-676.

相关文章 15

[1]	颜磊,岳彩欣,刘懿淳. 子宫内膜异位症的生育力保护[J]. 山东大学学报 (医学版), 2022, 60(9): 31-34.
[2]	冷金花,史精华. 子宫腺肌病的临床表现[J]. 山东大学学报 (医学版), 2022, 60(7): 1-5.
[3]	张艺馨,赵玉立,封丽. 超声特征及术前CA-125联合对51例卵巢交界性及Ⅰ期恶性肿瘤的鉴别诊断[J]. 山东大学学报 (医学版), 2022, 60(7): 104-109.
[4]	陈忠绍,褚然,李明宝,张向宁. MRKH综合征相关腹股沟子宫疝修补术后腹壁瘢痕子宫内膜异位症1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(5): 114-117.
[5]	林雪艳,张灿灿,田民乐,田永杰. 聚腺苷酸二磷酸核糖聚合酶-1在子宫内膜异位症中的表达及意义[J]. 山东大学学报 (医学版), 2022, 60(2): 27-31.
[6]	哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[7]	单婧,王晓秋,李大金. NK细胞参与子宫内膜异位症及其不孕的分子机制[J]. 山东大学学报 (医学版), 2021, 59(8): 8-13.
[8]	陈君宇, 曹冬焱. 以脑梗为首发的卵巢癌病例报告[J]. 山东大学学报 (医学版), 2021, 59(5): 110-112.
[9]	梁炎春,叶海花,陆丽美,戴郁菁,程谦益,蔡婉玲,曾涵秋,陈杏欢,王兴,韦雅婧,杨如玉. 慢性子宫内膜炎对子宫内膜异位症相关性不孕妊娠结局的影响[J]. 山东大学学报 (医学版), 2021, 59(3): 55-59.
[10]	薛源,林雪艳,徐歌,田永杰. 低氧诱导因子-1α在子宫内膜异位症患者血清中的表达和对在位子宫内膜间质细胞上皮-间质转化的影响[J]. 山东大学学报 (医学版), 2021, 59(2): 41-47.
[11]	潘虹江,王焕昇,裴发军,杨明山. 孤立性膀胱子宫内膜异位症1例[J]. 山东大学学报 (医学版), 2021, 59(2): 122-124.
[12]	王国云,王凯,袁明,陈子江. 子宫内膜异位症立体化管理体系(山东方案)[J]. 山东大学学报 (医学版), 2021, 59(10): 1-16.
[13]	王正阳,夏艳,师凯旋,陶琨,王小杰. 曲美替尼在卵巢癌中对PAX8的表达作用[J]. 山东大学学报 (医学版), 2021, 59(10): 23-29.
[14]	王宝金,赵欣欣,李霞,马倩,王新月,孙阳,史中娜. miR-203靶向Survivin抑制卵巢癌细胞增殖、迁移与侵袭[J]. 山东大学学报 (医学版), 2020, 58(12): 23-28.
[15]	冷金花,史精华. 子宫内膜异位症长期管理策略[J]. 山东大学学报 (医学版), 2019, 57(6): 1-5.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed